 In comparison, more expensive and complicated devices have been developed to address this similar problem. Wearable and implantable EEG-based seizure monitoring systems are in development, but thus far have only been tested in a few subjects that have a history of refractory epilepsy. Home health weight monitors and other devices are available, but demonstrate high costs and limited broad application, as they are only provided in conjunction with home health care internal data. In addition, more complicated telehealth monitoring, asking over 10 questions per call, with multiple triggers actually induces negligible effect on treatment outcomes in patients such as congestive heart failure. In comparison, implantable sensors for CHF have demonstrated increase in patient survival. 